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YET ANOTHER SULPHONYLUREA FOR LATE-ONSET DIABETICS
We seem to have a surfeit of blood-sugar lowering agents
for use in non-ketosis-prone, maturity-onset diabetics.
The sulphonylureas available in this country include tol-
butamide (Rastinon, Artosin), chlorpropamide (Diabi-
nese), acetohexamide (Dimelor), tolazamide (Tolazine)
and the closely-related glymidine or glycodiazine (Lyca-
nol, Gondafon). In addition we have the diguanides, phen-
formin (Insoral) and metformin (Glucophage). Although
there are minor differences between the sulphonylureas
with regard to power and speed of action, mechanism of
degradation, toxic effects and liability to cumulation and
hypoglycaemia, by and large they affect the same people
in the same way. If anything, the previously-believed dif-
ferences among the sulphonylureas have recently been
reduced. Thus it has become clear that all of them are
usually equally effective whether given in a single daily
dose or in divided doses, whatever their theoretical half-
life times may be.'
It is also evident that severe and long-lasting hypo-
glycaemic coma can occur even from the so-called short-
acting members of the family. Other severe side-effects
have been gratifyingly rare with all these drugs, despite
initial worries regarding jaundice and blood dyscrasias in
relation to some of them. Consequently, one must serious-
ly question what a new sulphonylurea has to offer and
why one should be persuaded to use it in preference to
old and trusted drugs of which one has had considerable
experience.
The new drug now on the market is glybenclamide,
tested under the cognomen HB419 and a joint product of
the two German pharmaceutical houses, Hoechst and
Boehringer-Mannheim (trade names Daonil and Euglu-
con). Since these two firms also produce and supply us
with the popular and successful sulphonylurea, tolbuta-
mide, they must have good reasons for launching a
second one some 12 or 13 years later. The reason ap-
pears to be simply that glybenclamide is very many times
more potent, weight for weight, in reducing blood-sugar
levels than any other sulphonylurea so far marketed. This
leads to the following possible advantages:
1. It may be more efficient in controlling diabetes.
2. The tablets are smaller and easier to swallow.
3. It may be cheaper.
4. It may have fewer toxic and side-effects.
Judging the relative efficacy of 2 sulphonylureas on
an outpatient basis is extremely difficult in individual
cases, unless the difference is very gross-one drug having
no apparent action and the other producing excellent
control. So many other variables enter into the test, such
as natural fluctuation, unequal division of parties, emo-
tional disturbances and personal bias, that one is, in ef-
fect, performing a very uncontrolled trial. To be sure of
a partial superiority of one drug over another in an indi-
vidual Case would necessitate the alternate use of each
drug several times. This we seldom do. It is therefore not
surprising that opinion is divided concerning the relative
efficacy of glybenclamide in comparison with other sul-
phonylureas.
In fact, as judged from the recent conference held on
this drug in Bavaria,' and from the articles concerned
with its trial in this country and reported in this issue of
the Journal;-' it would appear to be approximately as
efficacious as chlorpropamide-slightly less so in some
series. Of course the actual dose, weight for weight, is
considerably less in the case of glybenclamide, the maxi-
mum recommended dose being 10 - 20 mg./day as against
500 mg. for chlorpropamide, but this makes little dif-
ference to the patient, except for the possibility of put-
ting an equivalent dose in a smaller pill.
At the time of writing we are not aware of what the
price will be or how it will compare with other sulphonyl-
ureas. Because of the large amount of chemical research
work and pharmacological testing that culminated in gly-
benclamide, and also because of the rather complicated
side-chain, it may be no cheaper than other sulphonyl-
ureas. At a normal dose rate of 1 or 2 tablets a day, the
price per tablet will be able to be compared directly with
that of chlorpropamide; but the price of I tablet of gly-
benclamide should be compared with that of 2 tablets of
tolbutamide.
Toxicity has been shown by the makers to be very low
-the toxic action seems not to have increased with
therapeutic potency. Thus the oral LD", of sodium gly-
benclamide in the albino mouse is 3·5 G / kg. and of
to'butamide 1·8 G /kg.: while the LD50 of the original sub-
stance is over 15 G / kg. and of tolbutamide 2-5 G / kg. *
Other studies give comparable results. As reported at
the conference, there appear to have been no serious
toxic effects among some 6,000 patients who had been
concerned in trials of the drug, except possibly for 2 or
3 cases of jaundice which may have been coincidental.
Minor side-effects were seen, as with all trials of new
drugs, and even with placebos, but these were not severe
and seldom led to discontinuation of the drug. There
were a few allergic drug rashes, indicating that this sensi-
tivity reaction may occur even with very small amounts
of sulphonylureas. Schneider and Lopis' encountered
several side-effects in their series, many of which, how-
ever, were probably not caused by the drug itself but
possibly by the diguanide used in conjunction.
Although we may therefore expect toxic and side-
effects to be minimal with glybenclamide, this is not the
case with regard to hypoglycaemic reactions. These were
not a feature in the reports in this issue of the Journal,
but were frequently encountered by others as reported at
the conference.' Some authorities suggested that glyben-
c1amide should be used only after the less powerful tol-
butamide had failed, particularly in old people or those
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with very mild diabetes. It might be ufficient to re-
member that glybenclamide i highly potent in ome indi-
vidual, and to be careful, therefore, to tart with a very
small do e in such circumstances.
A with other sulphonylurea, glybenclamide is not
uitable for young diabetics who are liable to ketosis. It
wa reported from India that good control was frequently
achieved in young diabetics (who were not keto is-prone)
and we hall probably find the ame with South African
Indian. Again, as with other ulphonylurea ,'.8 glyben-
clamide has been hown to combine well with the
diguanide ,.., so that thi combination may salvage many
who would otherwise be failure on either drug alone. It
is al 0 clear that correct dieting will till be the corner-
stone of diabetic management, a it i in treatment with
insulin or any other drug. Again, as with other sulphonyl-
ureas, secondary failures do occur after initial months of
satisfactory control, but the frequency of these 's not yet
certain. Many of them can be brought under control
again if diguanides are used in conjun~tion. .
Has this drug justified itself? We bebeve that It has. It
i no panacea even for older diabetics, and there are
everal poor results in the presently reported trials..·• It
is in fact most unlikely that any further advance will be
made in tbi cla s of oral drug. It may represent the
ultimate ulphonylurea, and indeed it is to be hoped that
we are not further deluged with similarly potent com-
pounds produced by slight changes in the chemical side-
chain but offering no increased advantage.
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FIKSHEID
Ons verbeter gedurig op ons sportprestasie . Daar is haas
nie 'n sportbyeenkoms van enige omvang en status waar
daar nie 'n paar bestaande rekord gebreek word nie. As
mens in aanmerking neem dat noukeurige vasstelling en
aantekening van sportpresta ies nou reeds lank oral in die
wereId gedoen word, kom mens te taan voor die
interessante vraag: Waar gaan dit eindig? As ons jaar na
jaar vinnjger atlete oplei en mense wat hoer kan spring of
'n di ku verder kan gooi dan moet daar tog seker op 'n
gegewe stadium 'n eindpunt bereik word waar verby ons
nie al kan kom nie. Maar waar le daardie absolute limiet?
Sleg 'n paar d-;:kades geled wou die beste afrigters nie
graag byt aan die idee van 'n 4-minute myI nie. Dit sou
darem eens te veel gevrae wees, het hulle geredeneer. Van-
dag is daar talle mense wat 'n myI in minder as 4 minute
hard loop en sulke gebeurtenisse is nie eens meer koerant-
nuus nie. Wat nou van die 3-minute myl? Of is dit werklik
te veel gevra om van ons atlete te verwag dat hulle ook
hierdie grens moet oorskry?
Op feitlik alle gebiede van men like prestasies behalwe
die suiwer tegnologiese ontdekkings en atletiek, bestaan
daar hoogtepunte wat erken word as feitlik onverbeterbaar.
Die groot komponiste van die 1ge eeu en vele skilders,
digters en skrywers van vorige generasies sal altyd hul
grootheid behou. Maar daar is skaars 'n atletiek rekord op
enige van die portgebiede wat nie gedurende die afgelope
paar dekades 'n kerf hoer ge tel is nie; soms selfs her-
haaldelik. Daar is nie hoogspringers of spiesgooiers van
50 jaar gelede wie se rekords nou nog as a emrowende
hoogtepunte in die sportgeskiedenis aanvaar word nie.
Hierdie feite in aanmerking nemende moet ons dus een
van twee dinge aanvaar. Of on i vandag 'n veel beter en
fis;es sterker ras as ons voorvaders, Of dit is die beter kennis
van die vereistes van afrigting wat die prestasies so
indrukwekkend maak. In hierdie uitgawe publiseer ons 'n
artikel oor die vereistes waaraan sportmanne van wereld-
standaard behoort te voldoen. Dit is intere sant om te
sien dat die skrywers tot die slotsom kom dat lang-afstand
naellopers se prestasies nie noemenswaardig deur afrigting
verbeter word nje. Dit is dus een afdeling waar ons die
effek van verbeterde oefeningsmetodes kan negeer.
Dit is sekerlik waar dat die wereld se gesondheidstatus
oor die algemeen aan die verbeter is, maar sou dit so 'n
groot verskil kan maak aan die sport rekords by
Olimpiades? Geen land gaan tog sy cbronies ondervoede
burgers tuur om aan 'n internasionale byeenkoms deel te
neem nie, en dus moet mens aanvaar dat die fiksheid van
die hedendaagse atlete beter is as die van hul voorvaders.
Die mees waarskynlike verklaring vir ons gedurig ver-
beterende sportvermoe moet gesoek word in 'n samewer-
king tussen meerdere faktore: die verbetering in algemene
gesondheidstatus; die beter afrigting; groter bewustheid van
die belang van sulke prestasies en miskien nog vele ander
dinge. As mens kyk na die foto's van sportspanne van
weleer is dit opvallend hoe ondoeltreffend die kleredrag
dikwels was en mens kry dan die indruk dat doelgerigt-
heid nie die eerste oorweging was nie.
Maar, soos reeds gese, erens sal dit moet ophou. Ons
kan tog nie verwag dat met ons moderne gewiIligheid om al
die nodige te doen om prestasies te verbeter, die rekord nog
tot in die verre toekoms jaar na jaar opgeskuif gaan word
nie. Op die ou end salons die stadium moet bereik dat
ons die uiterste van menslike inspanningsvermoe in die
gesig staar, en dan sal die rekords jarelank onverbeterd op
die boeke moet bly staan en die toekomstige atlete sal slegs
kan probeer om die standaard te handhaaf, met min of
geen hoop om ooit daarop te verbeter nie. Dit sal beslis
neig om 'n dempende effek te he op die geesdrif van die
deelnemers en die toeskouers sal ook moet leer om nie
gedurig asemrowende nuwe hoogtes te verwag nie.
Dit is 'n interessante raaispeletjie om te probeer voorspel
presies waar die limiete gevind gaan word. Miskjen moet
ons nou 'n kassie eren inste] waarin die verskillende
raaiskote geberg kan word, vir ons nasate om te ontdek en
te sien hoe reg of verkeerd ons was.
